ABEONA THERAPEUTICS INC. (ABEO)
D
Pipeline Grade
Financial Position (from SEC Filings)
$61.4M
Cash & Equivalents
$19.8M
Quarterly Burn Rate
9 mo
Est. Cash Runway
$398M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05708677 | A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB | OTHER | Enrolling By Invitation | 22 |
| NCT05725018 | A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patien... | PHASE3 | Active Not Recruiting | 12 |
| NCT02716246 | Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH | PHASE3 | Recruiting | 36 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-04 | 8-K | ABEONA THERAPEUTICS INC. (ABEO) (CIK 0000318306) - 8-K | EDGAR |